Cite

    Reema Mody et al.. “Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States.” Diabetes, obesity & metabolism, vol. 21, no. 4, 2019, pp. 920–929. http://access.bl.uk/ark:/81055/vdc_100078578953.0x000019